A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

ClinicalTrials.gov ID: NCT01376297

Public ClinicalTrials.gov record NCT01376297. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Multicenter, Randomized, Double-blind, Unbalanced (3:1) Active Control Study to Assess the Safety and Describe the Efficacy of Netupitant and Palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.

Study identification

NCT ID: NCT01376297
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Helsinn Healthcare SA; Industry
Enrollment: 413 participants

Conditions and interventions

Conditions

Chemotherapy-Induced Nausea and Vomiting

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2011 (Type not available)
Primary completion: Sep 2012 (Actual)
Completion: Not listed
Last update posted: Nov 17, 2014

Started 2011

United States locations

U.S. sites: 11
U.S. states: 8
U.S. cities: 11

Facility	City	State	ZIP	Site status
Northwest Alabama Cancer Center PC	Muscle Shoals	Alabama	35661	—
East Valley Hematology and Oncology Medical Group	Burbank	California	91505	—
American Institute of Research	Los Angeles	California	90017	—
Veterans Administration New Jersey Health Care System	East Orange	New Jersey	07018	—
Hematology Oncology Associates of Rockland	Nyack	New York	10960	—
Hematology and Oncology Associates, Inc.	Canton	Ohio	44708	—
Tri-County Hematology & Oncology Associates, Inc	Massillon	Ohio	44646	—
Cancer Center at Memorial Hospital of RI	Pawtucket	Rhode Island	02860	—
Spartanburg Regional Health Services	Spartanburg	South Carolina	29303	—
South Texas Comrehensive Cancer Centers	Corpus Christi	Texas	78405	—
MD Anderson Cancer Center	Houston	Texas	77030-4009	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01376297, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 17, 2014 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01376297 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →